TNF-Inhibitor as Immune Checkpoint Inhibitor for Advanced MELanoma (TICIMEL)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03293784 |
|
Recruitment Status :
Active, not recruiting
First Posted : September 26, 2017
Last Update Posted : November 21, 2022
|
Sponsor:
Institut Claudius Regaud
Information provided by (Responsible Party):
Institut Claudius Regaud
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Actual Primary Completion Date : | December 6, 2019 |
| Estimated Study Completion Date : | November 2023 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):